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Abstract
Background: Different measures of non-adherence to immunosuppressant (IS) medication have been found to be
associated with rejection episodes after successful transplantation. The aim of the current study was to investigate
whether graft rejection after renal transplantation is associated with patient-reported IS medication non-adherence
and IS trough level variables (IS trough level variability and percentage of sub-therapeutic IS trough levels).
Methods: Patient-reported non-adherence, IS trough level variability, percentage of sub-therapeutic IS trough
levels, and acute biopsy-proven late allograft rejections were assessed in 267 adult renal transplant recipients
who were ≥12 months post-transplantation.
Results: The rate of rejection was 13.5%. IS trough level variability, percentage of sub-therapeutic IS trough levels as
well as patient-reported non-adherence were all significantly and positively associated with rejection, but not with
each other. Logistic regression analyses revealed that only the percentage of sub-therapeutic IS trough levels and
age at transplantation remained significantly associated with rejection.
Conclusions: Particularly, the percentage of sub-therapeutic IS trough levels is associated with acute rejections
after kidney transplantation whereas IS trough level variability and patient-reported non-adherence seem to be of
subordinate importance. Patient-reported non-adherence and IS trough level variables were not correlated; thus,
non-adherence should always be measured in a multi-methodological approach. Further research concerning the
best combination of non-adherence measures is needed.
Keywords: Kidney transplantation, Rejection, Patient-reported non-adherence, Immunosuppressant trough level
variability, Sub-therapeutic immunosuppressant trough levels
Background
Even after a long and frustrating time on the waiting
list followed by a successful transplantation, many pa-
tients develop problems with adherence to their im-
munosuppressant (IS) medication. There are different
ways to assess non-adherence, e.g. patient-report, family
report, physicians’ report, IS medication blood levels, refill
record count, electronic monitoring. Depending on the
operationalization, the prevalence of non-adherence varies
from 2–67% (see reviews of Denhaerynck et al. [1] and
Butler et al. [2]). Furthermore, the different non-adherence
measures are found to be only partly interrelated [3–7].
When comparing different methods of assessing IS
non-adherence, patient-report usually results in higher
non-adherence rates compared to other measures [3, 8];
however, even patient-reported non-adherence rates might
still underestimate the true non-adherence rate because
non-adherent patients could hesitate to admit their true
medication taking behavior [9]. Eventhough there is the
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risk of social desirability with patient-reported non-
adherence assessment (as it is with all self-report vari-
ables), patient-reported non-adherence has been shown
to be associated with rejection [1, 10–12] and graft loss
[1, 2, 6, 11, 13]. However, some studies failed to prove
this association [6, 14].
Variability of IS trough levels as well as sub-therapeutic
IS trough levels have been associated with late rejections
and even graft loss in both pediatric and adult patients
undergoing different kinds of solid organ transplantation
[1, 10, 15–25]. Hsiau et al. [24] as well as Borra et al. [22]
reported an association of IS trough level variables and
late rejection only for tacrolimus, but not for mycopheno-
lic acid. On the other hand, Fredericks et al. [26] and
Tielen et al. [6] did not find tacrolimus level variability to
be associated with rejections.
In Germany, psycho-social support of transplant pa-
tients is one of the objectives of psychosomatic care,
including also the optimization of medication adher-
ence as a part of health behavior. As measuring non-ad-
herence via patient-report might be distorted by social
desirability and electronic medication monitoring systems
are expensive and impractical for clinical routine, we
intended to investigate if variability of IS trough levels as
well as sub-therapeutic IS trough levels might be easy
assessable objective parameters of patients’ medication ad-
herence behavior and also a potential outcome measure
for adherence trainings.
The aim of the present study was to investigate whether
graft rejection after renal transplantation is associated with
patient-reported IS medication nonadherence and/or IS
trough level variables (IS trough level variability and the
percentage of sub-therapeutic IS trough levels) and




This multi-center study was performed at the trans-
plant centers of the University Hospitals of Erlangen
and Cologne and of Hannover Medical School and in-
cluded 267 consecutive adult patients who had undergone
renal transplantation between 1981 and 2014. Inclusion
criteria encompassed:
1) being ≥12 months post transplantation,
2) availability of ≥ 4 IS trough levels within the last
12 months before the non-adherence assessment;
levels within the first 6 months after transplantation
were not included; thus, in patients who were
12 months after transplantation, through levels of
only 6 months were included,
3) no additional non-renal transplantation,
4) no severe mental disorder,
5) no cognitive impairment, and
6) sufficient German language skills for understanding
of the questionnaires.
Institutional ethic board approval was obtained from
the Clinical Ethics Committee of the University Hospital
Erlangen (Friedrich-Alexander-Universität Erlangen-
Nürnberg (FAU)), the Clinical Ethics Committee of
Hannover Medical School, and the Ethics Committee of
the University Hospital of Cologne. All participants gave
written informed consent.
Assessment of patient-reported non-adherence was
conducted between November 2014 and December
2015 when participants were at the respective trans-
plant centers for routine follow-up examinations.
Trained medical staff, who were not part of the trans-
plant team, approached the patients and distributed the
questionnaires. IS trough levels and biopsy-proven graft
rejections from the last maximal 12 months before the
non-adherence assessment were recorded from the pa-
tient charts.
Assessment of patient-reported IS medication non-
adherence
For the assessment of patient-reported IS medication
non-adherence, the Basel Assessment of Adherence to
Immunosuppressive Medications Scale (BAASIS©; [27])
was used. It consists of four items concerning adherence
to IS medication (dose taking, drug holidays, timing
deviation >2 h from prescribed time, dose reduction) to
be rated on a 6-point scale (0 = never, 5 = every day).
Non-adherence is defined as at least one affirmative
answer to any of the four items (dichotomous score).
Following a systematic review of self-report instruments
to identify medication non-adherence, the BAASIS© was
recommended as a reliable, valid, and sensitive tool [27].
IS trough levels
We assessed two variables concerning IS medication
(tacrolimus, cyclosporine, everolimus, sirolimus) trough
levels: IS trough level variability and percentage of sub-
therapeutic IS trough levels. IS trough level data were
assessed from ethylenediamine tetraacetic acid (EDTA)
blood samples via LC-MS/MS (liquid chromatography
mass spectrometry/mass spectrometry) in Erlangen and
Hannover and via immune-assays in Cologne. IS trough
levels that were measured during hospitalization or
apparently shortly after IS intake were excluded as
invalid. The minimal number of valid IS trough levels
for calculation of IS trough level variability and percent-
age of sub-therapeutic IS trough levels was four, because
the medication levels from several time points are
thought to be more valid than a single medication level
from one time point [10].
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IS trough level data were standardized for the individ-
ual target level by dividing every single trough level by
its respective target level. The target level is determined
individually for each patient and can be changed by the
transplant physicians depending on the clinical course.
Thus, the target levels can differ both inter-patient and
intra-patient. By dividing every single level by the re-
spective target level, we controlled for changing target
levels and excluded variation due to those changes. For
these standardized trough levels, means (M) and stand-
ard deviations (SD) were calculated. We used intra-
patient coefficients of variation (CV) as a measure for
IS trough level variability, as suggested by Hsiau et al.
[24]. The CV was calculated by dividing the SD by the
respective M. The higher the CV, the more erratic are
the IS trough levels. The percentage of sub-therapeutic
IS trough levels was calculated by dichotomizing every
single IS trough level for each patient (< or ≥ the respect-
ive target level) and determining the proportion of sub-
therapeutic IS trough levels for each patient (0–100%).
Late rejections
All patients were transplanted ≥12 months prior. Late
rejection was defined as any biopsy-proven acute
rejection ≥6 months after transplantation. Rejections
that occurred more than 12 months before the patient-
reported non-adherence assessment were excluded
from the analysis. Thereby, we analyzed an assessment
period of 12 months, which began 6 months to 34 years
after the last transplantation.
Statistical analyses
In the case of missing variables the patient was excluded
from the respective analysis. Two patients (0.7% of the
whole sample) did not provide self-report non-adherence
data. For an overview, M, SD, ranges, and frequencies (as
appropriate) for all variables are given. A logistic regres-
sion model was conducted with rejection being the
dependent variable and patient-reported non-adherence,
IS trough level variability, percentage of sub-therapeutic
IS trough levels, and age at transplantation as independent
variables. Preliminary analyses comprised Pearson, point-
biserial and Spearman correlation coefficients as well as
group comparisons (Mann-Whitney-U-tests and Chi2-
tests). Statistical analyses were conducted with the statis-
tical analysis program SPSS 21. Findings were considered
to be statistically significant at p < 0.05. Due to the ex-
plorative character of the study, no correction for multiple
testing was conducted.
Results
Socio-demographic and biomedical data
A total of 267 patients were included in the analyses
(35% females); the mean age at assessment was 52.8 years
and the incidence of late allograft rejection 13.5%. For
detailed information, please see Table 1.
Correlation analyses and group differences
IS trough level variability, percentage of sub-therapeutic
IS trough levels, and patient-reported non-adherence
were all three significantly correlated with late allograft
rejection.
Patients with and without rejections did not differ
significantly from each other regarding sex, time since
last transplantation, dialysis before transplantation, IS
medication type and number of IS trough levels, but did
differ regarding age and age at transplantation. Therefore,
age and age at transplantation were also considered as po-
tential independent variables for regression analyses.
To avoid problems of multicollinearity in the following
regression analyses, we conducted correlation analyses be-
tween the independent variables: IS trough level variabil-
ity, percentage of sub-therapeutic IS trough levels, and
patient-reported non-adherence were not correlated with
each other. Patient-reported non-adherence (BAASIS) was
significantly correlated with age and age at transplant-
ation. However, r was <0.150, so we assumed the correl-
ation to be small enough to be negligible for the
regression analysis. As was to be expected, age and age at
transplantation were significantly correlated with each
other (r = 0.908, p < 0.001). Consequently, we decided to
Table 1 Socio-demographic and biomedical data
All patients (N = 267)
Sex (females: n, %) 93 (35%)
Age (in years; M, SD, range) 52.8 ± 13.7 (18–80)
Age at transplantation
(in years; M, SD, range)
45.8 ± 14.7 (2–76)
Time since last transplantation
(in years; M, SD, range)















Number of IS trough levels
(M, SD, range)
9.6 ± 4.3 (4–37)
IS trough level variability
(M, SD, range)
21.3 ± 10.2 (2.7–56.1)
Percentage of sub-therapeutic IS
trough levels (M, SD, range)
42.3 ± 27.6 (0–100%)
Patient-reported non-adherence (n, %) 89 (33%)
Scheel et al. BMC Nephrology  (2017) 18:107 Page 3 of 7
include only one variable in the regression analysis. We
chose age at transplantation, because its correlation with
rejection was somewhat stronger (−0.246, p < 0.001 for
age at transplantation versus −0.197, p = 0.001 for age).
Regression model
The full model including all independent variables ex-
plained 18.9% of the variance. Age at transplantation and
the percentage of sub-therapeutic IS trough levels reached
significance, whereas IS trough level variability and
patient-reported non-adherence did not. The odds ratio
was particularly high for the percentage of sub-therapeutic
IS trough levels (OR 6.136; 95% CI 1.524–24.708). Includ-
ing patient-reported non-adherence increased the amount
of explained variance only non-significantly by 1.4%. For
details, please see Table 2. The results did not change,
when the regression analysis was repeated by including
only tacrolimus medication. For the other IS medication
groups, the samples were too small to conduct separate
regression analyses.th=tlb=
Discussion
Our main findings are as follows: (1) IS trough level
variability, percentage of sub-therapeutic IS trough
levels, and patient-reported non-adherence were all
three associated with rejection, but not with each other.
(2) Logistic regression analysis revealed that rejection
was significantly associated with a higher percentage of
sub-therapeutic IS trough levels and younger age at
transplantation.
The rate of late allograft rejection within the last
12 months (6 months to 34 years after the last trans-
plantation) was 13.5% in our sample and therefore com-
parable to other studies. Three studies with assessment
periods of 12–24 months (11 months to 15 years post
transplantation; excluding the first 6 months post trans-
plantation) reported rejection rates of 9.9–10.1% [15, 17,
18]. Rejection rates of 10.5–11.2% were reported by two
studies with assessment periods of 12 months (1–7.7 years
post transplantation; under inclusion of the first 6 months
post transplantation) [22, 26]. In contrast, rejection rates
from 21.7 to 42.4% were found in some studies [6, 16, 20,
21, 23–25], but these might be due to longer assessment
periods than in our study and the inclusion of the first
6 months after transplantation (0.5–8.5 years after trans-
plantation), when most complications and especially most
acute rejections occur.
When comparing IS trough level variability in different
studies, it has to be kept in mind that different measures
have been used for the calculation of IS trough level
variability. Several researchers used the SD to express IS
trough level variability [3, 16–18, 20, 23, 24, 26]. The
problem with SD is that it skews toward individuals with
higher mean IS trough levels [24]. Therefore, a
standardization with the mean, i.e. the CV, is preferable
[15, 19, 21, 24, 25, 28] and has also been found to be
more reliable [24]. By using standardization by the target
level instead of the unstandardized blood levels we ex-
cluded variation due to changing IS target levels for
medical reasons [10] in the present study. Other studies
have also corrected for drug dosage, but the formula was
not specified in detail [21, 22]. These different ap-
proaches to measure IS trough level variability must be
taken into account when comparing different studies.
We found a mean IS trough level variability (CV) of
21.26%, with a SD of 10.16% ranging from 2.74 to
56.08% (median 19.67%). Compared to other studies
using the CV, this was quite low [15, 21, 24, 25, 28].
Similarly to our results, Tielen et al. [6] found that IS
trough level variability was not associated with patient-
reported non-adherence (BAASIS).
Apart from IS trough level variability, the percentage
of sub-therapeutic IS trough levels was particularly
associated with late allograft rejection. Also other in-
vestigators have found low/sub-therapeutic IS trough
levels to be associated with late rejection [20, 25] and
even graft loss [15].
That self-reported non-adherence is only correlatively
associated with rejections, but no longer in regression
analyses (outperformed by age and the percentage of
sub-therapeutic IS trough levels) might be due to non-
adherence self-reports being contaminated by memory
biases and social desirability and to rejections being not
only influenced by non-adherence but also by variables
like sub-therapeutic IS trough levels. Similarly, the lack
of association between patient-reported non-adherence
and IS trough level variables is likely due to the fact that
the IS trough level variables do not only display non-


















Age at transplantation −0.047 (0.013) 12.581 0.954 0.929–0.979 0.000 0.112 <0.001 193.810
Percentage of sub-therapeutic
IS trough levels
1.814 (0.711) 6.515 6.136 1.524–24.708 0.011 0.160 <0.001 0.006 186.339
IS trough level variability 0.029 (0.018) 2.566 1.029 0.994–1.066 0.109 0.175 <0.001 n.s. 183.941
Patient-reported non-adherence 0.586 (0.387) 2.292 1.796 0.841–3.835 0.130 0.189 <0.001 n.s. 181.679
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adherence behavior, but can also be caused by drug-
drug interactions or other pharmacokinetic factors
[17, 18, 29–33]. Patient-reported non-adherence is not
equivalent to a high IS trough level variability or to a
high percentage of sub-therapeutic IS trough levels,
but is an important reason for a high variability and/
or sub-therapeutic levels, that needs to be recognized.
Therefore, also the percentage of sub-therapeutic IS
trough levels might be a potential outcome measure
for adherence trainings though it is not associated
with patient-reported non-adherence.
When comparing the rate of patient-reported non-
adherence (BAASIS) in our study, similar results were
obtained in other studies in adult [8, 10] and pediatric
[11] renal transplant recipients (30–40%). Lennerling et
al. [34] even found 54% of the patients to be non-
adherent according to the BAASIS. Yet, it has to be kept
in mind that these data might be subject to a recruit-
ment bias (non-adherent patients might be more likely
to refuse study participation than adherent patients)
and/or social desirability.
Younger age is considered to be a risk factor for
poor adherence when comparing adolescents with
adults [1, 20], this might be due to adolescence-related
issues like concerns about body image, developmental
tasks related to autonomy and self-identity, cognitive
development (abstract thinking, behavioral control
and responsibility), and risk taking / experimentation
[35, 36]. Our study was conducted only in adults and
revealed that patients, who experienced rejection, received
renal transplantation at a younger age than patients with
no rejection (36.6 ± 15.7 years vs. 47.2 ± 14.0 years old at
the time of transplantation). Similarly, Borra et al. [22] re-
ported recipient age at transplantation to be a significant
risk factor for poor long-term outcome in adult renal
transplant recipients (mean recipient age at transplant-
ation was 41 years for the kidney failure group and
48 years for the control group). Younger adult age at
transplantation might be associated with rejection and
also with poorer patient-reported adherence due to a
lower perceived threat of disease and multiple stressors
regarding family and professional activity in younger years.
Yet, our data are not sufficient to finally show whether
non-adherence contributes to the poorer outcome of
younger patients.
There are several limitations to our study. Firstly, our
study is retrospective (IS trough level variability, sub-
therapeutic IS trough levels) and cross-sectional (patient-
reported non-adherence). Thus causal interpretations
should be made with caution. Furthermore, IS trough level
variability and sub-therapeutic IS trough levels were
assessed both before and after rejection and rejections
can be followed by IS dose adjustments and might
change IS trough level variables and also patient-reported
non-adherence. Yet, we would expect this fact to minimize
associations between rejections, patient-reported non-
adherence, IS trough level variability, and sub-therapeutic
IS trough levels. Therefore, the association could even be
stronger in prospective studies (beginning with the assess-
ment of self-reported non-adherence). Secondly, we did
not assess other risk factors of acute rejection, such as the
presence or new onset of infections by which drug expos-
ure could be influenced. Thirdly, we only considered the
IS medications to be regularly measured in the three
transplant centers and ignored additional IS medications
(e.g. mycophenolate mofetil, cortisone) and non-IS medi-
cations (e.g. antihypertensive drugs). Furthermore, IS
trough level data were assessed with different methods
(via LC-MS/MS in Erlangen and Hannover and via
immune-assays in Cologne). However, these different
methods should have negligible effects because of the
standardization by target levels and calculation of the CV.
Finally, we did not use electronic medication monitoring
systems as a more objective reference method for non-
adherence. Such methods are considered as closest to a
gold standard in measuring non-adherence, but they are
expensive and impractical for clinical routine [10].
Conclusion
Sub-therapeutic IS trough levels, high IS trough level
variability and patient-reported non-adherence are
each associated with late acute rejection in renal
transplant patients. However, they are not significantly
associated with each other. Particularly, the percent-
age of sub-therapeutic IS trough levels seems to be
strongly associated with acute rejections after kidney
transplantation whereas IS trough level variability and
patient-reported non-adherence seem to be of subor-
dinate importance. Patient-reported non-adherence
and IS trough level variables seem to measure differ-
ent facets of non-adherence and cannot replace each
other. Consequently, non-adherence should always be
measured in a multi-methodological approach. Further
research concerning the best combination of non-
adherence measures is needed. Moreover, younger age
at transplantation should be considered as a risk factor
of rejection.
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